Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease
Launched by MASSACHUSETTS GENERAL HOSPITAL · Jun 9, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well a telehealth program can help patients with moderate to severe chronic graft-versus-host disease (cGVHD), a condition that can occur after a stem cell or bone marrow transplant. The program focuses on providing palliative care, which means it aims to improve the quality of life for patients by managing symptoms and providing support, rather than trying to cure the disease. The study is currently recruiting participants who are adults over 18 years old, speak and understand English, and have been assessed by their healthcare provider as having moderate to severe cGVHD.
If you decide to participate, you'll be involved in a program that uses technology to connect with healthcare providers from the comfort of your home. This is a proof-of-concept study, meaning it's an early stage trial to see if the approach works well. Participants will need to be able to understand and respond to questions in English, as the study materials are in that language. It's important to note that individuals with serious psychiatric or cognitive conditions that could affect their ability to participate or provide consent, or those who are currently receiving palliative care, will not be eligible for this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1) Adult patients (\>18 years)
- • 2) Have moderate to severe cGVHD based on their oncology clinician assessment as documented in the electronic health record.
- • 3) Ability to comprehend and speak English, and to read and respond to questions in English
- • Please note that this is a proof-of-concept study, and we only include patients who comprehend, read, and respond to questions in English since the study instruments are all available in English. However, as we have done in prior studies, we will expand the population in a future efficacy trial.
- Exclusion Criteria:
- • 1) Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believe prohibits informed consent or compliance with study procedures
- • 2) Patients who have already consulted or are currently consulting palliative care
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported